Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

The firm has strong confidence aTyr’s lead program efzofitimod will be successful in its ongoing Phase 3 study in pulmonary sarcoidosis, with topline results expected in Q3 2025. The Phase 3 EFZO-FIT ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Feb. 6, 2025 — Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including ...